Prevention and treatment of acute graft-versus-host disease: The old and the new. A report from the Eastern Cooperative Oncology Group (ECOG)

Bone Marrow Transplantation

Volumn 19, Issue 6, 1997, Pages 577-600

  Lazarus, H M ^a,d   Vogelsang, G B ^b   Rowe, J M ^c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c STRONG MEMORIAL HOSPITAL   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Cyclosporine; Cytokines; Graft versus host disease; Monoclonal antibodies; Prednisone; Transplantation

Indexed keywords

15 DEOXYSPERGUALIN; ANTIBODY CONJUGATE; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; DEFEROXAMINE; DENILEUKIN DIFTITOX; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID; PENICILLAMINE; PREDNISONE; RAPAMYCIN; RICIN ANTIBODY; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; XOMAZYME;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTHRALGIA; CENTRAL NERVOUS SYSTEM DISEASE; CHILL; CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; EYE TOXICITY; FATIGUE; FEVER; GRAFT VERSUS HOST REACTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOTENSION; IMMUNOLOGICAL TOLERANCE; INCIDENCE; LETHARGY; LEUKEMIA; MORBIDITY; MORTALITY; NAUSEA; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PUVA; RESPIRATORY DISTRESS; REVIEW; SIDE EFFECT; VOMITING;

EID: 0030934464     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700710     Document Type: Review

References (374)

1. Martin PJ, Hansen JA, Storb R, Thomas ED. Human marrow transplantation: an immunological perspective. Adv Immunol 1987; 40: 379-389.
2. Gale RP. Graft-versus-host disease. Immunol Rev 1985; 88: 193-214.
3. Bortin MM, Horowitz MM, Mrsic M et al. Progress in bone marrow transplantation for leukemia: a preliminary report from the Advisory Committee of the International Bone Marrow Transplant Registry. Transplant Proc 1991; 23: 61-62.
4. Hansen JA, Anasetti C, Martin PJ et al. Allogeneic marrow transplantation: the Seattle experience. In: Terasaki PI, Cecka JM (eds). Clinical Transplantation. UCLA Tissue Typing Laboratory: Los Angeles, 1994, pp 193-209.
5. Sullivan KM. Graft-versus-host disease. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific: Oxford, 1994, pp 339-362.
6. Trentin JJ. Mortality and skin transplantability in irradiated mice receiving isologous or heterologous bone marrow. Proc Soc Exp Biol Med 1956; 92: 688-693.
7. Barnes DWH, Loutit JF. Spleen protection. the cellular hypothesis. In: Bacq ZM (ed). Radiobiology Symposium Liège. Butterworths: London, 1955, pp 134-135.
8. Billingham RE. The biology of graft-versus-host reactions. The Harvey Lectures 1966-67, Vol 62. Academic: New York, Academic, 1966, pp 21-78.
9. Vogelsang GB. Acute and chronic graft-versus-host disease. Curr Opin Oncol 1993; 5: 276-281.
10. Parkman R. Human graft-versus-host disease. Immunodef Rev 1991; 2: 253-264.
11. Parkman R. Graft-versus-host disease. Anna Rev Med 1991; 42: 189-197.
12. Ferrara JLM, Deeg HJ. Graft-versus-host disease. New Engl J Med 1991; 324: 667-674.
13. Wagner JE Jr, Vogelsang GB, Beschorner WE. Pathogenesis and pathology of graft-versus-host disease. Am J Pediatr Hematol Oncol 1989; 11: 196-212.
14. Bortin MM, Rimm AA. Treatment of 144 patients with severe aplastic anemia using immunosuppression and allogeneic marrow transplantation. A report from the International Bone Marrow Transplantation Registry. Transplant Proc 1981; 13: 227-229.
15. Weisdorf D, Haake R, Blazar B et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024-1030.
16. Report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1989; 4: 221-228.
17. Aschan J, Ringdén O. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease. Clin Transplant 1994; 8: 258-270.
18. Weisdorf D, Hakke R, Blazar B et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991; 51: 1197-1203.
19. Eisner MD, August CS. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. Bone Marrow Transplant 1995; 15: 663-668.
20. Ramsay NKC, Kersey JH, Robison LL et al. A randomized study of the prevention of acute graft-versus-host disease. New Engl J Med 1982; 306: 392-397.
21. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
22. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. New Engl J Med 1993; 328: 593-602.
23. Beatty PG, Clift RA, Mickelson EM et al. Marrow transplantation from related donors other than HLA-identical siblings. New Engl J Med 1985; 313: 765-771.
24. Beatty PG, Hansen JA, Anasetti C et al. Marrow transplantation from unrelated HLA-matched volunteer donors. Transplant Proc 1989; 21: 2993-2994.
25. Beatty PG. Results of allogeneic bone marrow transplantation with unrelated or mismatched donors. Semin Oncol 1992; 19: 13-19.
26. Gluckman E, Belanger C, Bourdeau H, Raffoux C, French results of bone marrow transplantation using unrelated HLA matched donors. Bone Marrow Transplant 1990; 5 (Suppl. 2): 8 (Abstr. 14).
27. Bacigalupo A, Hows J, Gordon-Smith EC et at. Bone marrow transplantation for severe aplastic anemia from donors other than HLA identical siblings: a report of the BMT Working Party. Bone Marrow Transplant 1988; 3: 531-535.
28. Beatty PG, Anasetti C, Hansen JA et al. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood 1993; 81: 249-253.
29. Beatty PG, Hansen JA, Longton GM et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991; 51: 443-447.
30. Hings IM, Severson R, Filipovich AH et al. Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation. Transplantation 1994; 58: 437-442.
31. Sullivan KM. Graft-versus-host disease. In: Blume KG, Petz LD (eds). Clinical Bone Marrow Transplantation. Churchill-Livingstone: New York, 1983, pp 91-129.
32. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long term clinical pathological study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
33. Sullivan KM, Shulman HM, Storb R et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981: 57: 267-276.
34. Sullivan KM. Acute and chronic graft-versus-host disease in man. Inr J Cell Cloning 1986; 4: 42-93.
35. Atkinson K, Horowitz MM, Gale RP et al. Risk factors for chronic graft versus host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75: 2459-2464.
36. Atkinson K. Chronic graft-versus-host disease. Bone Marrow Transplant 1990; 5: 69-82.
37. Deeg HJ. Graft-versus-host disease: host and donor views. Semin Hematol 1993; 30 (Suppl. 4): 110-118.
38. 1 hybrid rats. Ann NY Acad Sci 1962; 99: 432-455.
39. McGregor DD. Bone marrow origin of immunologically competent lymphocytes in the rat. J Exp Med 1968; 127: 953-966.
40. Theobald M. Allorecognition and graft-versus-host disease. Bone Marrow Transplant 1995; 15: 489-498.
41. Korngold R, Sprent J. T cell subsets in graft-versus-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds). Graft-versus-host Disease: Immunology, Pathophysiology, and Treatment. Marcel Dekker: New York, 1990, pp 31-50.
42. Kernan NA, Collins NH, Juliano L et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-versus-host disease. Blood 1986; 68: 770-773.
43. Anasetti C, Howe C, Petersdorf EW et al. Marrow transplants from HLA matched unrelated donors: an NMDP update and the Seattle experience. Bone Marrow Transplant 1994; 13: 693-695.
44. Behar E, Chao NJ, Hiraki DD et al. Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease. New Engl J Med 1996; 334: 286-291.
45. Goulmy E, Schipper R, Pool J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. New Engl J Med 1996; 334: 281-285.
46. Schreuder GMT, Pool J, Blokland E et al. A genetic analysis of human minor histocompatibility antigens demonstrates Mendelian segregation independent of HLA. Immunogenetics 1993; 38: 98-105.
47. Gluckman E, Devergie A, Sohier J, Saurat JH. Graft-versus-host disease in recipients of syngeneic bone marrow. Lancet 1980; 1: 253-254.
48. Thein SL, Goldman JM, Galton DG. Acute 'graft-versus-host disease' after autografting for chronic granulocytic leukaemia in transplantation. Ann Intern Med 1981; 94: 210-211.
49. Rappeport J, Mihm M, Reinherz E et al. Acute graft-versus-host disease in recipients of bone marrow transplantation from identical twin donors. Lancet 1979; 2: 717-720.
50. Hess AD, Horwitz L, Beschorner WE, Santos GW. Development of graft-versus-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity. J Exp Med 1985; 161: 718-730.
51. Hess AD, Fischer AC. Immune mechanisms in cyclosporine-induced syngeneic graft-versus-host disease. Transplantation 1989; 48: 895-900.
52. Hood AF, Vogelsang GB, Black LP et al. Acute graft-versus-host disease: development following autologous and syneneic bone marrow transplantation. Arch Dermatol 1987; 123: 745-750.
53. Yeager AM, Vogelsang GB, Jones RJ et al. Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 1992; 79: 3031-3035.
54. Jenkins MK, Schwartz RH, Pardoll DM. Effects of cyclosporine A on T cell development and clonal deletion. Science 1988; 241: 1655-1658.
55. Guillen FJ, Ferrara J, Hancock WW et al. Acute cutaneous graft-versus-host disease to minor histo-compatibility antigens in a murine model: evidence that large granular lymphocytes are effector cells in the immune response. Lab Invest 1986; 55: 35-42.
56. Ghayur T, Seemayer TA, Lapp WS. Kinetics of natural killer cell cytotoxicity during the graft-versus-host reaction. Relationship between natural killer cell activity, T and B cell activity, and development of histopathological alterations. Transplantation 1987; 44: 254-260.
57. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-2968.
58. Ferrara JLM, Abhyankar S, Gilliland DG. Cytokine storm of graft-versus-host disease: a critical effect role for interleukin-1. Transplant Proc 1993; 25: 1216-1217.
59. Jadus MR, Wepsic HT. The role of cytokines in graft-versus-host reactions and disease. Bone Marrow Transplant 1992; 10: 1-14.
60. Ferrara J, Burakoff S. The pathophysiology of acute graft-versus-host disease in a murine bone marrow transplant model. In: Burakoff S, Deeg HJ, Ferrara J, Atkinson K (eds). Graft-versus-host Disease: Immunology, Pathophysiology and Treatment. Marcel Dekker: New York, 1990, pp 9-29.
61. Ferrara JLM. Cytokine dysregulation as a mechanism of graft versus host disease. Curr Opin lmmunol 1993; 5: 794-799.
62. Theobald M. Predicting graft-versus-host disease. Curr Opin Immunol 1995; 7: 649-655.
63. Chao NJ. Graft versus host disease following allogeneic bone marrow transplantation. Curr Opinion Oncol 1992; 4: 571-576.
64. Pirsch JD, Maki DG. Infectious complications in adults with bone marrow transplantation and T cell depletion of donor marrow: increased susceptibility to fungal infections. Ann Intern Med 1986; 104: 619-631.
65. Atkinson K, Storb R, Prentice RL et al. Analysis of late infections in 89 long term survivors of bone marrow transplantation. Blood 1979; 53: 720-731.
66. Meyers J. Infection in bone marrow transplant recipients. Am J Med 1986; 81 (Suppl. 1A): 27-38.
67. Sable CA, Donowitz GR. Infections in bone marrow transplant recipients. Clin Infect Dis 194; 18: 273-284.
68. Lerner KG, Kao GF, Storb R et al. Histopathology of graft-vs-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant Proc 1974; 6: 367-371.
69. Woodruff JM, Hansen JA, Good RA et al. The pathology of the graft-versus-host reaction (GVHR) in adults receiving bone marrow transplants. Transplant Proc 1976; 8: 675-684.
70. Sale GE, Lerner KG, Barker EA et al. The skin biopsy in the diagnosis of acute graft-versus-host disease in man. Am J Pathol 1977; 89: 621-635.
71. Deeg HJ, Cottler-Fox M. Clinical spectrum and pathophysiology of acute graft-versus-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds). Graft-versus-Host Disease: Immunology, Pathophysiology, and Treatment. Marcel Dekker: New York, 1990, pp 311-335.
72. Vogelsang GB, Hess AD, Santos GW. Acute graft-vs-host disease: clinical characteristics in the cyclosporine era. Medicine (Baltimore) 1988; 67: 163-174.
73. Graw RG Jr, Santos GW. Bone marrow transplantation in patients with leukemia. Incidence and severity of graft-vs-host disease and successful HLA-matched transplants. Transplantation 1971; 11: 197-199.
74. Hershko C, Gale RP. GVHD scoring system for predicting survival and specific mortality in bone marrow transplant recipients. In: Gale RP (ed). Biology of Bone Marrow Transplantation. Academic Press: New York, 1980, pp 159-169.
75. Vogelsang GB. Acute graft-vs-host disease. In: Champlin R (ed). Bone Marrow Transplantation. Kluwer Academic Publishers: Boston, 1990, pp 55-67.
76. Atkinson K, Horowitz MM, Biggs JC et al. The clinical diagnosis of acute graft-versus-host disease: a diversity of views amongst marrow transplant centers. Bone Marrow Transplant 1988; 3: 5-10.
77. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
78. Rowlings P et al. A new system for grading acute graft-versus-host disease. Keystone Conference, January 1996, Keystone, Colorado.
79. Atkinson K, Horowitz M, Gale RP et al. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Bone Marrow Transplant 1989; 4: 247-254.
80. Schiller G, Gale RP. Is there an effective therapy for chronic graft-versus-host disease? Bone Marrow Transplant 1993; 11: 189-192.
81. Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. New Engl J Med 1990; 323: 315-321.
82. Hathaway WE, Fulginiti VA, Pierce CW et al. Graft-vs-host reaction following a single blood transfusion. JAMA 1967; 201: 1015-1020.
83. Hathaway WE, Githens JH, Blackburn WR el al. Aplastic anemia, histiocytosis and erythrodermia in immunologically deficient children. Probable human runt disease. New Engl J Med 1965; 273: 953-958.
84. Greenbaum BH. Transfusion-associated graft-versus-host disease: historical perspectives, incidence, and current use of irradiated blood products. J Clin Oncol 1991; 9: 1889-1902.
85. Wagner FF, Flegel WA. Transfusion-associated graft-versus-host disease: risk due to homozygous HLA haplotypes. Transfusion 1995; 35: 284-291.
86. Fast LD, Valeri CR, Crowley JP. Immune responses to major histocompatibility complex homozygous lymphoid cells in murine F1 hybrid recipients: implications for transfusion-associated graft-versus host disease. Blood 1995; 86: 3090-3096.
87. Birz M, Cabrera R, Sanjuan I et al. Diagnosis of a transfusion-associated graft-versus-host disease by polymerase chain reaction in fludarabine-treated B-chronic lymphocytic leukaemia. Br J Haematol 1995; 91: 409-411.
88. Maung ZT, Wood AC, Jackson GH et al. Transfusion-associated-graft versus host disease in fludarabine-treated B-chronic lymphocytic leukaemia. Br J Haematol 1994; 88: 649-652.
89. Siimes MA, Koskimies S. Chronic graft versus host disease after blood transfusions confirmed by incompatible HLA antigens in bone marrow. Lancet 1982; 1: 42-43 (letter).
90. von Fliedner V, Higby DJ, Kim U. Graft-versus-host reaction following blood production transfusion. Am J Med 1982; 72: 951-961.
91. Huang SW, Ammann AJ, Levy RL et al. Treatment of severe combined immunodeficiency by a small number of pretreated nonmatched marrow cells. Transplantation 1973; 15: 174-176.
92. Mori S, Matsushita H, Ozaki K et al. Spontaneous resolution of transfusion-associated graft-versus-host disease. Transfusion 1995; 35: 431-435.
93. Yasukawa M, Shinozaki F, Hato T et al. Successful treatment of transfusion-associated graft-versus-host disease. Br J Haematol 1994; 86: 831-836.
94. Thomas ED, Storb R, Clift RA et al. Bone-marrow transplantation. New Engl J Med 1975; 292: 832-843.
95. Davey RJ. Transfusion-associated-graft versus host disease and the irradiation of blood components. Immunol Invest 1995; 24: 431-434.
96. Leitman SF, Holland PV. Irradiation of blood products. Indications and guidelines. Transfusion 1985; 25: 293-303.
97. Anderson KC, Goodnough LT, Sayers M et al. Variation in blood component irradiation practice: implications for prevention of transfusion-associated graft-versus-host disease. Blood 1991; 77: 2096-2102.
98. Drobyski W, Thibodeau S, Truitt RL el al. Third-party-mediated graft rejection and graft-versus-host disease after T-cell-depleted bone marrow transplantation, as demonstrated by hypervariable DNA probes and HLA-DR polymorphism. Blood 1989; 74: 2285-2294.
99. Akahoshi M, Takanashi M, Masuda M et al. A case of transfusion-associated-graft versus host disease not prevented by white cell-reduction filters. Transfusion 1992; 32: 169-172.
100. Storb R, Prentice RL, Buckner CD et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protected environment. New Engl J Med 1983; 308: 302-307.
101. Lazarus HM, Coccia PF, Herzig RH et al. Incidence of acute graft-versus-host disease with and without methotrexate prophylaxis in bone marrow transplant patients. Blood 1984; 64: 215-220.
102. Elfenbein G, Goedert T, Graham-Pole J et al. Is prophylaxis against acute graft-versus-host disease necessary if treatment is effective and survival not impaired. Proc Am Soc Clin Oncol 1986; 5: 643 (Abstr. 643).
103. Sullivan KM, Deeg HJ, Sanders J et al. Hyperacute graft-versus-host disease in patients not given immunosuppression after allogeneic marrow transplant. Blood 1986; 67: 1172-1175.
104. Vogelsang GB, Hess AD, Berkman AW et al. An in vitro predictive test for graft versus host disease in patients with genotypic HLA-identical bone marrow transplants. New Engl J Med 1985; 313: 645-650.
105. Thomas ED, Storb R, Clift RA et al. Bone-marrow transplantation. New Engl J Med 1975; 292: 895-902.
106. Santos GW, Owens AH. A comparison of the effects of selected cytotoxic agents on allogeneic skin graft survival in rats. Bull Johns Hopkins Hosp 1965; 116: 327-329.
107. Doney KC, Weiden PL, Storb R, Thomas ED. Failure of early administration of antithymocyte globulin to lessen graft-versus-host disease in human allogeneic marrow transplant recipients. Transplantation 1981; 31: 141-143.
108. Weiden PL, Doney K, Storb R, Thomas ED. Anti-human thymocyte globulin for prophylaxis of graft-versus-host disease: a randomized trial in patients with leukemia treated with HLA-identical sibling matched grafts. Transplantation 1979; 27: 227-230.
109. Tutschka PJ, Beschorner WE, Allison AC et al. Use of cyclosporin A in allogeneic bone marrow transplantation in the rat. Nature 1979; 280: 148-151.
110. Barrett AJ, Kendra JR, Lucas CF et al. Cyclosporin A as prophylaxis against graft-versus-host disease in 36 patients. Br Med J 1982; 285: 162-166.
111. Gluckman E, Arcese W, Devergie A, Boiron M. Cyclosporin-A prophylactic treatment of graft-versus-host disease in human allogeneic bone marrow transplantation: preliminary results. Transplant Proc 1981; 13: 368-370.
112. Gratwohl A, Osterwalder B, Ruggers D et al. Prophylaxis of graft-versus-host disease with cyclosporine A. Blut 1980; 41: 180-181.
113. Powles RL, Clink HM, Spence D et al. Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation. Lancet 1980; 1: 327-329.
114. Tutschka PJ, Beschorner WE, Hess AD, Santos GW. Cyclosporine-A to prevent graft-versus-host disease: a pilot study in 22 patients receiving allogeneic marrow transplants. Blood 1983; 61: 318-325.
115. Hows JM, Palmer S, Gordon-Smith EC. Use of cyclosporin A in allogeneic bone marrow transplantation for severe aplastic anemia. Transplantation 1982; 33: 382-386.
116. Gluckman E, Devergie A, Lokiec F. Use of cyclosporine for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Transplant Proc 1988; 20 (Suppl. 3): 461-469.
117. Bacigalupo A, Frassoni F, van Lint MT et al. Cyclosporine A in marrow transplantation for leukemia and aplastic anemia. Exp Hematol 1985; 13: 244-248.
118. Biggs JC, Atkinson K, Gillett E et al. A randomized prospective trial comparing cyclosporine and methotrexate given for prophylaxis of graft-versus-host disease after bone marrow transplantation. Transplant Proc 1986; 18: 253-255.
119. Deeg HJ, Storb R, Thomas ED et al. Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute non-lymphocytic leukemia. Blood 1985; 65: 1325-1334.
120. Storb R, Deeg HJ, Thomas ED et al. Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. Blood 1985; 66: 698-702.
121. Gale RP, Bortin MM, van Bekkum DW et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987; 67: 397-406.
122. Storb R, Deeg HJ, Farewell V et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986; 68: 119-125.
123. Nash RA, Pepe MS, Storb R et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838-1845.
124. Tollemar J, Ringdén O, Sundberg B et al. Decreased incidence of graft-versus-host disease in bone marrow transplantation recipients treated with a combination of cyclosporine and methotrexate. Transplant Proc 1988; 20: 494-498.
125. Tollemar J, Ringdén O, Heimdahl A et al. Decreased incidence and severity of graft-versus-host disease in HLA matched and mismatched marrow recipients of cyclosporine and methotrexate. Transplant Proc 1988; 20 (Suppl. 3): 470-479.
126. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
127. Clift RA, Buckner CD, Thomas ED el al. The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 1987; 2: 243-258.
128. Storb R, Deeg HJ, Pepe M et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73: 1729-1734.
129. Santos GW, Tutschka PJ, Brookmeyer R et at. Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: a randomized double-blind study in patients undergoing allogeneic marrow transplantation. Clin Transplant 1987; 1: 21-28.
130. Shepherd JD, Shore TB, Reece DE et al. Cyclosporine and methylprednisolone for prophylaxis of acute graft-versus-host disease. Bone Marrow Transplant 1988; 3: 553-558.
131. Forman SJ, Blume KG, Krance RA et al. A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: methotrexate/prednisone v Cyclosporine A/prednisone. Transplant Proc 1987; 19: 2605-2607.
132. Galimberti M, Polchi P, Lucarelli G et al. A comparative trial of post-transplant immunosuppression in patients transplanted for thalessemia. Cyclosporine alone versus cyclosporine, cyclophosphamide, and methotrexate. Transplantation 1988; 45: 566-569.
133. Lindholm A, Ringdén O, Lonnqvist B. The role of cyclosporine dosage and plasma levels in efficacy and toxicity in bone marrow transplant recipients. Transplantation 1987; 43: 680-684.
134. Holler E, Kolb HJ, Hiller E et al. Microangiopathy in patients on Cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood 1989; 73: 2018-2024.
135. Juckett M, Terry EH, Daniels BS, Weisdorf DJ. Hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant 1991; 7: 405-409.
136. Donatsch P, Abisch E, Homberger M et al. A radioimmunoassay to measure cyclosporin A in plasma and serum sample. J Immunoassay 1981; 2: 19-32.
137. Yee GC, Self SG, McGuire TR et al. Serum Cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. New Engl J Med 1988; 319: 65-70.
138. Yee GC, Kennedy MS, Deeg HJ et al. Cyclosporine-associated renal dysfunction in marrow transplant recipients. Transplant Proc 1985; 17: 196-201.
139. Gratwohl A, Speck B, Wenk M et al. Cyclosporine in human bone marrow transplantation. Serum concentration, graft-versus-host disease, and nephrotoxicity. Transplantation 1983; 26: 40-44.
140. Atkinson K, Biggs JC, Hayes J et al. Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: three distinct syndromes. Br J Haematol 1983; 54: 59-67.
141. Miller KB, Schenkein D, Erban J et al. Continuous infusion cyclosporin for the prevention of graft versus host disease. Blood 1990; 76: 554a (Abstr. 2206).
142. Deeg HJ, Spitzer TR. Cottler-Fox M et al. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. Bone Marrow Transplant 1991; 7: 193-198.
143. Phillips GL, Barnett MJ, Brain MC et al. Allogeneic bone marrow transplantation using unrelated donors: a pilot study of the Canadian Bone Marrow Transplant Group. Bone Marrow Transplant 1991; 8: 477-487
144. Roy J, McGlave PB, Filipovich AH et al. Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplant 1992; 10: 77-82.
145. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990; 76: 1867-1871.
146. Storb R, Pepe M, Anasetti C et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 1990; 76: 1037-1045.
147. Chao NJ, Schmidt C, Nilan J et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. New Engl J Med 1993; 329: 1225-1230.
148. Yau JC, LeMaistre CF, Zagars GK et al. Methylprednisolone, cyclosporine and methotrexate for prophylaxis of acute graft-versus-host disease. Bone Marrow Transplant 1990; 5: 269-272.
149. Chao NJ, Schlegel PG, Nademanee AP et al. Drug prophylaxis for acute graft-versus-host disease. Bone Marrow Transplant 1995; 15 (Suppl. 1): S94-S97.
150. Sullivan KM, Kopecky KJ, Jacom J et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. New Engl J Med 1990; 324: 631-634.
151. Sullivan KM, Storek J, Kopecky KJ et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-versus-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant 1996; 2: 44-53.
152. Phillips GL, Nevill TJ, Spinelli JJ et al. Prophylaxis for acute graft-versus-host disease following unrelated donor bone marrow transplantation. Bone Marrow Transplant 1995; 15: 213-219.
153. Nash RA, Etzioni R, Storb R et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. Blood 1995; 85: 3746-3753.
154. Przepiorka D, Ipoliti C, Khouri I et al. Tacrolimus vs cyclosporine for prevention of acute graft-versus-host disease (GVHD) after allogeneic blood stem cell transplantation. Blood 1995; 86 (Suppl. 1): 395a (Abstr. 1568).
155. Liu J, Farmer JD Jr, Lane WS et al. Calcineurin is a common target of cyclophilin-cyclosporine A and FKBP-FK506 complexes. Cell 1991; 66: 807-815.
156. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992; 357: 695-697.
157. Raff RF, Storb R, Graham T et al. Pharmacologie, toxicologic and marrow transplantation studies in dogs given succinyl acetone. Transplantation 1992; 54: 813-820.
158. Raff RF, Storb R, Graham T et al. What role for 15-deoxyspergualin in enhancing engraftment of unrelated, histoincompatible canine marrow grafts and preventing graft-versus-host disease? Transplantation 1993; 55: 684-688.
159. Tufveson G, Gannedahl G. Deoxyspergualin - a different and intriguing immunosuppressant. Transplant Proc 1994; 26: 3029-3039.
160. Mrowka C, Thoenes GH, Langer KH, Bartlett RR. Prevention of the acute graft-versus-host disease (GVHD) in rats by the immunomodulating drug leflunomide. Ann Hematol 1994; 68: 195-199.
161. Sykes M, Szot GL, Nguyen PL, Pearson DA. Interleukin-12 inhibits murine graft-versus-host disease. Blood 1995; 86: 2429-2438.
162. Schwinghammer TL, Bloom EJ. Pharmacologie prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation. Clin Pharmacy 1993; 12: 736-761.
163. Pietryga D. Prevention and treatment of acute graft-vs-host disease. Am J Pediatr Hematol Oncol 1993; 15: 28-48.
164. Vogelsang GB, Morris LE. Prevention and management of graft-versus-host disease. Practical recommendations. Drugs 1993; 45: 668-675.
165. Collins RH, Pineiro LA, Nemunaitis JJ et al. Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation. Transfusion 1995; 35: 891-898.
166. Kolb H-J, Mittermüller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
167. Bar BM, Schattenberg A, Mensick EJ et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 1993; 11: 513-519.
168. Drobyski WR, Keever CA, Roth MS et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310-2318.
169. Hertenstein B, Wiesneth M, Novotny J et al. Interferon-α and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transplantation 1993; 56: 1114-1118.
170. Szer J, Grigg AP, Phillips GL, Sheridan WP. Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. Bone Marrow Transplant 1993; 11: 109-111.
171. Helg C, Roux E, Beris P et al. Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplant 1993; 12: 125-129.
172. Porter DL, Roth MS, McGarigle C et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. New Engl J Med 1994; 330: 100-106.
173. van Rhee F, Lin F, Cullis JO et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 3377-3383.
174. Kolb H-J, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
175. Mackinnon S, Papadopoulos EB, Carabasi HM et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-1268.
176. Fischer A. The use of monoclonal antibodies in allogeneic bone marrow transplantation. Br J Haematol 1993; 83: 531-534.
177. O'Reilly RJ. T-cell depletion and allogeneic bone marrow transplantation. Bone Marrow Transplant 1992; 7: 20-26.
178. Marmont AM, Horowitz MM, Gale RP et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
179. O'Reilly RJ, Collins NH, Brochstein J et al. Soybean lectinagglutination and E-rosette depletion for removal of T-cells from HLA-identical marrow grafts: results in 60 consecutive patients transplanted for hematologic malignancy. In: Hagenbeek A, Lawenbery B (eds). Minimal Residual Disease in Acute Leukemia. Nijhoff: Dordrecht, 1986, pp. 337-344.
180. O'Reilly RJ. T-cell depletion and allogeneic bone marrow transplantation. Semin Hematol 1992: 29 (Suppl. 1): 20-26.
181. Champlin R. T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation. Hematol Oncol Clin North Am 1990; 4: 687-698.
182. Kelemen E, Szebeni J, Petrányi GG. Graft-versus-host disease in bone marrow transplantation: experimental, laboratory, and clinical contributions of the last few years. Int Arch Allergy lmmunol 1993; 102: 309-320.
183. Butturini A, Gale RP. T-cell depletion in bone marrow transplantation for leukemia: current results and future directions. Bone Marrow Transplant 1988; 3: 185-192.
184. Poynton CH. T cell depletion in bone marrow transplantation. Bone Marrow
185. Vallera DA, Blazar BR. T cell depletion for graft-versus-host-disease prophylaxis. A perspective on engraftment in mice and humans. Transplantation 1989; 47: 751-760.
186. Champlin R. T-cell depletion for allogeneic marrow transplantation: innovations to enhance engraftment and graft-versus-leukemia. Bone Marrow Transplant 1995; 15 (Suppl. 1 ): S104-S111.
187. Reisner Y, Martelli MF. Successful engraftment of T-cell depleted incompatible bone marrow supplemented with peripheral blood stem cells: from animal models to clinical application in leukemia patients. Bone Marrow Transplant 1995; (Suppl. 1): S112-S118.
188. Drobyski WR, Ash RC, Casper JT et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 1994: 83: 1980-1987.
189. Antin JH, Bierer BE, Smith BR et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 1991; 78: 2139-2149.
190. Waldmann H, Cobbold S, Hale G. What can be done to prevent graft versus host disease? Curr Opinion Immunol 1994; 6: 777-783.
191. Sykes M. Novel approaches to the control of graft versus host disease. Curr Opinion Immunol 1993; 5: 774-781.
192. Aversa F, Tabilio A, Terenzi A el al. Successful engraftment of T-cell-depleted haploidentical three-loci incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84: 3948-3955.
193. Hale G, Waldmann H. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant 1994; 13: 597-611.
194. Ringdén O, Remberger M, Aschan J el al. Long-term follow-up of a randomized trial comparing T cell depletion with a combination of methotrexate and cyclosporine in adult leukemic marrow transplant recipients. Transplantation 1994; 58: 887-891.
195. Martin PJ. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans. J Exp Med 1993; 178: 703-712.
196. Kernan NA. Strategies to prevent graft rejection following T-cell depleted unrelated marrow transplantation. Bone Marrow Transplant 1995; 15 (Suppl. 1): S92-S93.
197. Kaufman CL, Colson YL, Wren SM et al. Phenotypic characterization of a novel bone marrow marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood 1994; 84: 2436-2446.
198. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806-814.
199. Lasky LC, van Buren N, Weisdorf DJ et al. Successful allogeneic cryopreserved marrow transplantation. Transfusion 1989: 29: 182-184.
200. Eckardt JR, Roodman GD, Boldt DH et al. Comparison of engraftment and acute GVHD in patients undergoing cryopreserved or fresh allogeneic BMT. Bone Marrow Transplant 1993; 11: 125-131
201. Castro J, Bachier C, Boldt DH et al. Cryopreserved matched related donor marrow engrafts promptly following allogeneic bone marrow transplantation. Blood 1994; 84 (Suppl. 1): 93a (Abstr. 361).
202. Ringdén O. Management of graft-versus-host disease. Eur J Haematol 1993; 51: 1-12.
203. Storb R. Pathogenesis and recent therapeutic approaches to graft-versus-host disease. J Pediatr 1991; 118 (Suppl.): 10-13.
204. Deeg HJ, Henslee-Downey PJ. Management of acute graft-versus-host disease. Bone Marrow Transplant 1990; 6: 1-8.
205. Parr MD, Messino MJ, McIntyre W. Allogeneic bone marrow transplantation: procedures and complications. Am J Hosp Practice 1991; 48: 127-137.
206. Klingemann HG, Barnett MJ, Reece DE et al. Use of an immunoglobulin preparation enriched for IgM (Pentaglobulin) for the treatment of acute graft-versus-host disease. Bone Marrow Transplant 1990; 6: 199-202.
207. Sullivan KM, Witherspoon RP, Storb R et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-versus-host disease. Blood 1988; 72: 555-561.
208. Powles RL, Barrett AJ, Clink H et al. Cyclosporine A for the treatment of graft-versus-host disease in man. Lancet 1978; 2: 1327-1331.
209. Kennedy MS, Deeg HJ, Storb R et al. Treatment of acute graft-versus-host disease after allogeneic marrow transplantation: a randomized study comparing corticosteroids and cyclosporine. Am J Med 1985; 78: 978-983.
210. Deeg HJ, Loughran TP Jr, Storb R et al. Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. Transplantation 1985; 40: 162-166.
211. Kendra J, Barrett AJ, Lucas C et al. Response of graft-versus-host disease to high doses of methylprednisolone. Clin Lab Haematol 1981; 3: 19-26.
212. Bacigalupo A, van Lint MT, Frassoni F et al. High dose bolus methylprednisolone for the treatment of acute graft-versus-host disease. Blut 1983; 46: 125-132.
213. Kanojia MD, Anagnostou AA, Zander AR et al. High-dose methylprednisolone treatment for acute graft-versus-host disease after bone marrow transplantation in adults. Transplantation 1984; 37: 246-249.
214. Storb R, Gluckman R, Thomas ED et al. Treatment of established human graft-versus-host disease by anti-thymocyte globulin. Blood 1974; 44: 57-75.
215. Doney KC, Weiden PL, Storb R, Thomas ED. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteriods. Am J Hematol 1981; 11: 1-8.
216. Weiden PL, Doney K, Storb R, Thomas ED. Anti-human thymocyte globulin (ATG) for prophylaxis and treatment of graft-versus-host disease in recipients of allogeneic marrow grafts. Transplant Proc 1978; 10: 213-216.
217. DuToit DF, Heydenrych JJ. The application, mechanism of action and side-effects of immunosuppressive agents in clinical transplantation. S Afr Med J 1986; 70: 687-691.
218. Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990; 76: 1464-1472.
219. Socie G, Selimi F, Sedel L et al. A vascular necrosis of bone after allogeneic bone marrow transplantation: clinical findings, incidence and risk factors. Br J Haematol 1994; 86: 624-628.
220. Sayer HG, Longton G, Bowden R et al. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. Blood 1994; 84: 1328-1332.
221. Kings IM, Filipovich AH, Miller WJ et al. Prednisone therapy for acute graft-versus-host disease: short-versus longterm treatment. A prospective randomized trial. Transplantation 1993; 56: 577-580.
222. Hansen JA, Petersdorf EW, Choo SY et al. Marrow transplantation from HLA partially matched relatives and unrelated donors. Bone Marrow Transplant 1995; 15 (Suppl. 1): S128-S139.
223. Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991; 77: 1821-1828.
224. Hooks MA. Tacrolimus, a new immunosuppressant - a review of the literature. Ann Pharmacol 1994; 28: 501-511.
225. Hoffman AL, Makowka L, Banner B et al. The use of FK-506 for small intestine allotransplantation. Transplantation 1990; 49: 483-490.
226. Demetris AJ, Fung JJ, Todo S et al. FK 506 used as rescue therapy for human liver allograft recipients. Transplant Proc 1991; 23: 3005-3006.
227. Jordan ML, Shapiro R, Vivas CA et al. FK506 'rescue' for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994; 57: 860-865.
228. Armitage JM, Fricker FJ, Del Nido P et al. The clinical trial of FK506 as primary and rescue immunosuppression in pediatric cardiac transplantation. Transplant Proc 1991; 23: 3058-3060.
229. Markus PM, Cai X, Selvaggi G et al. The effect of cyclosporine, rapamycin, and FK506 the survival following allogeneic bone marrow transplantation. Transplant Proc 1991; 23: 3232-3233.
230. Markus PM, Cai X, Ming W et al. Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation 1991; 52: 590-594.
231. Cooper MH, Markus PM, Cai X et al. Prolonged prevention of acute graft-versus-host disease after allogeneic bone marrow transplantation by donor pre-treatment using FK506. Transplant Proc 1991; 23: 3238-3239.
232. Cooper MH, Patrene KD, Vecchini F et al. Short-term myeloid reconstitution following TBI is not adversely affected by doses of FK506 that abrogate lethal GVHD. Bone Marrow Transplant 1994; 14: 355-362.
233. Tzakis AG, Abu-Elmagd K, Fung JJ et al. FK-506 rescue in chronic graft-versus-host disease after bone marrow transplantation. Transplant Proc 1991; 23: 3225-3227.
234. Markus PM, Cai X, Ming W et al. FK506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. Surgery 1991; 110: 357-363.
235. Koehler MT, Howrie D, Mirro J et al. FK506 (tacrolimus) in the treatment of steroid-resistant acute graft versus host disease in children undergoing bone marrow transplantation. Bone Marrow Transplant 1995; 15: 895-899.
236. Kanamaru A, Takemoto Y, Kakishita E et al. FK506 treatment of graft-versus-host disease developing or exascerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Bone Marrow Transplant 1995; 15: 885-889.
237. Reinherz EL, Geha R, Rappeport JM et al. Reconstitution after transplant with T-lymphocyte-depleted HLA haplotypemismatched bone marrow for severe combined immunodeficiency. Proc Natl Acad Sci USA 1982; 79: 6047-6051.
238. Martin PJ, Shulman HM, Schubach WH et al. Fatal Epstein-Barr virus-associated proliferation of donor B cells following treatment of acute-graft-versus host disease with a murine anti-T-cell antibody. Ann Intern Med 1984; 101: 310-315.
239. Gratama JW, Jansen J, Lopovich RA et al. Treatment of acute graft-vs-host disease with monoclonal antibody OKT3. Transplantation 1984; 38: 469-474.
240. Gluckman E, Devergie A, Varin F et al. Treatment of steroid resistant severe acute graft-vs-host disease with a monoclonal pan T OKT3 antibody. Exp Hematol 1984: 12 (Suppl.): 66-67.
241. Martin PJ, Hansen JA, Anasetti C et al. Treatment of acute graft-versus-host disease with anti-CD3 monoclonal antibodies. Am J Kid Dis 1988; 11: 149-152.
242. Beelen DW, Graeven U, Schulz G et al. Treatment of acute graft-versus-host disease after HLA-partially matched marrow transplantation with a monoclonal antibody (BMA031) against the T cell receptor. First results of a phase-I/II trial. Onkologie 1988; 11: 56-58.
243. Remlinger K, Martin PJ, Hansen JA et al. Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft versus host disease. Human Immunol 1984; 9: 21-26.
244. Anasetti C, Martin PJ, Storb R et al. Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody. Transplantation 1992; 54: 844-851.
245. Hebart H, Ehninger G, Schmidt H et al. Treatment of steroidresistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies. Bone Marrow Transplant 1995; 15: 891-894.
246. Heslop HE, Benaim E, Brenner MK et al. Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1. Lancet 1995; 346: 805-806.
247. Billing R, Wells J, Zettel D, Terasaki PI. Monoclonal and heteroantibody reacting with different antigens common to human blast cells and monocytes. Hybridoma 1982; 1: 303-310.
248. Takahashi H, Okazaki H, Terasaki PI et al. Reversal of transplant rejection by monoclonal antiblast antibody. Lancet 1983; 2: 1155-1158.
249. Streilin JW. A common pathogenesis for the lesions of graft-versus-host disease. Transplant Proc 1971; 3: 418-421.
250. Van Els CACM, Bakker A, Zwinderman AH et al. Effector mechanisms in graft-versus-host disease in response to minor histocompatibility antigens. I. Absence of correlation with cytotoxic effector cells. Transplantation 1990; 50: 62-66.
251. Van Els CACM, Bakker A, Zwinderman AH et al. Effector mechanisms in graft-versus-host disease in response to minor histocompatibility antigens. II. Evidence of a possible involvement of proliferative T cells. Transplantation 1990; 50: 67-71.
252. Van Els CACM, Zantvoort E, Jacobs N et al. Graft-versus-host disease associated T helper cell responses specific for minor histocompatibility antigens are mainly restricted by HLA-DR molecules. Bone Marrow Transplant 1990; 5: 365-372.
253. Vogelsang GB, Hess AD. Perspective. Graft-versus-host disease: new directions for a persistent problem. Blood 1994; 84: 2061-2067.
254. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993; 54: 167-227.
255. Pober JS, Cotran RS. The role of endothelial cells in inflammation. Transplantation 1990; 50: 537-544.
256. Dinarello CA, Wolff SM. Mechanisms of disease: the role of interleukin-1 in disease. New Engl J Med 1993; 328: 106-113.
257. Abhyankar S, Gilliland D, Ferrara J. Interleukin 1 is a critical effector molecule during cytokine dysregulation and graft-versus-host disease to minor histocompatibility antigens. Transplantation 1993; 56: 1518-1523.
258. McIntyre KW, Stepan GJ, Kolinsky KD et al. Inhibition of interleukin-1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J Exp Med 1991; 173: 931-939.
259. McCarthy PL, Abhyankar S, Neben S et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 1991; 78: 1915-1918.
260. Vallera DA, Taylor PA, Vannice JL et al. Interleukin-1 and tumor necrosis factor-α antagonists do not inhibit graft-versus-host disease induced across the major histocompatibility barrier in mice. Transplantation 1995; 60: 1371-1374.
261. Antin JH, Weinstein HJ, Guinan EC et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994; 84: 1342-1348.
262. Shalaby MR, Fendly B, Sheehan K et al. Prevention of the graft-versus-host reaction in newborn mice by antibodies to tumor necrosis factor alpha. Transplantation 1989; 47: 1057-1061.
263. Symington FW, Pepe MS, Chen A, Deliganis A. Serum tumor necrosis factor alpha associated with acute graft-versus-host disease in humans. Transplantation 1990; 50: 518-521.
264. Piguet PF, Grau GE, Allet B et al. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 1987; 166: 1280-1289.
265. Piguet PF. Tumor necrosis factor and graft-versus-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds). Graft-versus-Host Disease: Immunology, Pathophysiology and Treatment. Marcel Dekker: New York, 1990, pp 225-276.
266. Nestel FP, Price KS, Seemayer T, Lapp W. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor a during graft-versus-host disease. J Exp Med 1992; 175: 405-413.
267. Dickinson AM, Sviland L, Carey P et al. Skin explant culture as a model for cutaneous graft-versus-host disease in humans. Bone Marrow Transplant 1988; 3: 323-329.
268. Dickinson AM, Sviland L, Dunn J et al. Demonstration of direct involvement of cytokines in graft-versus-host reactions using an in vitro human skin explant model. Bone Marrow Transplant 1991; 7: 209-216.
269. Wong G, Goeddel DV. Tumor necrosis factor alpha and beta inhibit virus replication and synergise with interferons. Nature 1986; 323: 819-822.
270. Loetscher H, Gentz R, Zulauf M et al. Recombinant 55-kDa tumor necrosis factor (TNF) receptor. J Biol Chem 1991; 266: 18324-18329.
271. Holler E, Kolb HJ, Möller A et al. Increased serum levels of tumor necrosis factor α preceed major complications of bone marrow transplantation. Blood 1990; 75: 1011-1016.
272. Holler E, Kolb HJ, Hintermeier-Knabe R et al. Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. Transplant Proc 1993; 25: 1234-1236.
273. Hervé P, Racadot E, Wijdenes J et al. Monoclonal anti-TNF alpha antibody in the treatment of acute GVHD refractory both to corticosteroids and anti-IL-2R antibody (abstract). Bone Marrow Transplant 1991; 7 (Suppl. 2): 149.
274. Hervé P, Flesch M, Tiberghien P et al. Phase I-II trial of monoclonal anti-tumor necrosis factor alpha for the treatment of refractory severe acute graft-versus-host disease. Blood 1992; 79: 3362-3368.
275. Hervé P, Tiberghien P, Racadot E et al. Prevention and treatment of acute GVHD: new modalities. Bone Marrow Transplant 1993; 11 (Suppl. 1): 103-106.
276. Hervé P, Racadot E, Wendling D et al. Use of monoclonal antibodies in vivo as a therapeutic strategy for alloimmune or autoimmune reactivity: the Besancon Experience, Immunol Rev 1992; 129: 31-55.
277. Hervé P, Bordigoni P, Cahn JY et al. Use of monoclonal antibodies in vivo as a therapeutic strategy for acute GVHD in matched and mismatched bone marrow transplantation. Transplant Proc 1991; 23: 1692-1694.
278. Holler E, Kolb HJ, Wilmanns W. Treatment of GVHD -TNF-antibodies and related antagonists. Bone Marrow Transplant 1993; 12 (Suppl. 3): S29-S31 (Abstr.).
279. Theobald M, Nierle T, Bunjes D et al. Host-specific interleukin-2 secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. New Engl J Med 1992; 327: 1613-1617.
280. Alessandrine EP, Bernascoui P, Colombo A. Levels of soluble low affinity IL2 receptors (s-IL2R) and TNF in the serum after bone marrow transplantation. Bone Marrow Transplant 1991; 7 (Suppl. 2): 51.
281. Siegert W, Josimovic-Alasevic O, Schwerdtfeger R et al. Soluble interleukin 2 receptors in patients after bone marrow transplantation. Bone Marrow Transplant 1990; 6: 97-101.
282. Strom TB, Kelley VE, Murphy JR et al. Interleukin 2 receptor directed immunosuppressive therapy. In: Smith KA (ed). Interleukin 2. Academic Press: New York, 1988, pp 223-236.
283. Belanger C, Esperou-Bourdeau H, Raffoux C, Gluckman E. Unrelated bone marrow transplant. Use of IL2 receptor monoclonal antibody (IL2-R-Ab) in prophylaxis of GVHD (abstract). Bone Marrow Transplant 1991; 7 (Suppl. 2): 122.
284. Belanger C, Esperou-Bourdeau H, Bordigoni P et al. Use of an anti-interleukin-2 receptor monoclonal antibody for GVHD prophylaxis in unrelated donor BMT. Bone Marrow Transplant 1993; 11: 293-297.
285. Tiley C, Powles R, Teo CP et al. Treatment of acute graft-versus-host disease with a monoclonal antibody to the IL-2 receptor (abstract). Bone Marrow Transplant 1991; 7 (Suppl. 2): 151.
286. Cuthbert RJG, Phillips GL, Barnett MJ et al. Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy. Bone Marrow Transplant 1992; 10: 451-455.
287. Cahn JY, Bordigoni P, Tiberghien P et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Transplantation 1995; 60: 939-942.
288. Ferrara JLM, Marion A, McIntyre JF et al. Amelioration of acute graft-versus-host disease due to minor histocompatibility antigens by in vivo administration of anti-interleukin 2 receptor antibody. J Immunol 1986; 137: 1874-1877.
289. Biaise D, Guyotat D, Reiffers J et al. Prospective randomized study of GVHD prevention using an anti IL2 receptor (CD25) MoAb after allogeneic bone marrow transplantation (BMT). Bone Marrow Transplant 1991; 7 (Suppl. 2): 150 (Abstr.).
290. Biaise D, Olive D, Hirn M et al. Prevention of acute graft-versus-host disease by in vivo anti-interleukin-2 receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients. Bone Marrow Transplant 1991; 8: 105-111.
291. Blaise D, Maranchini D, Mawas C et al. Prevention of acute graft-versus-host disease by monoclonal antibody to interleukin-2 receptor. Lancet 1989; 1: 1333-1334.
292. Hervé P, Wijdenes J, Bergerat JP et al. Treatment of acute graft-versus-host disease with monoclonal antibody to interleukin-2 receptor. Lancet 1988; 2: 1072-1073.
293. Hervé P, Wijdenes J, Bergerat JP et al. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10). Blood 1990; 75: 1017-1023.
294. Tiberghien P, Racadot E, Lioure B et al. Soluble CD8, IL-2 receptor, and tumor necrosis factor-alpha levels in steroid-resistant acute graft-versus-host disease. Relation with subsequent response to anti-IL-2 receptor monoclonal antibody treatment. Transplantation 1991; 52: 475-480.
295. Anasetti C, Martin PJ, Hansen JA et al. A phase I-II study evaluating a murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease. Transplantation 1990; 50: 49-54.
296. Anasetti C, Hansen JA, Waldmann T et al. Treatment of graft-versus-host disease with a humanized monoclonal antibody specific for the interleukin-2 receptor. Blood 1992; 80 (Suppl. 1): 373a (Abstr. 1484).
297. Queen C, Schneider WP, Selick HE et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci 1989; 86: 10029-10033.
298. Anasetti C, Hansen JA, Waldmann TA et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994; 84: 1320-1327.
299. Salzman D, LeMaistre F. Immunotoxins for the therapy of graft versus host disease. In: Rosen ST, Kuzel TM (eds). Immunoconjugate Therapy of Hematologic Malignancies. Kluwer Academic Publishers: Norwell, MA, 1993, pp 133-144.
300. Kernan NA, Byers V, Scannon PJ et al. Treatment of steroid-resistant acute graft-versus-host disease by in vivo administration of an anti-T-cell ricin A chain immunotoxin. J Am Med Assoc 1988; 259: 3154-3157.
301. Byers VS, Henslee PJ, Kernan NA et al. Use of anti-pan T-lymphocyte ricin A chain immunotoxin in steroid-resistant acute graft-versus-host disease. Blood 1990; 75: 1426-1432.
302. Lomen PL, Stewart KK, Saks SR. Safety and efficacy of H65-RTA in the treatment of steroid-resistant acute graft-versus-host disease after allogeneic bone marrow transplantation. Blood 1991; 78 (Suppl. 1): 230.
303. Lomen P. Anti-CD5 immunoconjugates in acute GVHD. In: Champlin RE, Gale RP (eds). New Strategies in Bone Marrow Transplantation. Alan R Liss: New York, 1990, pp 285-293.
304. Racadot E, Milpied N, Bordigoni P et al. Sequential use of three monoclonal antibodies in corticosteroid-resistant acute GVHD: a multicentric pilot study including 15 patients. Bone Marrow Transplant 1995; 15: 669-677.
305. Hellmann K. Immunosuppression by thalidomide: implications for teratology. Lancet 1966; 1: 1136-1137.
306. Mellin GW, Katzenstein M. The saga of thalidomide. New Engl J Med 1962; 267: 1184-1192.
307. Vogelsang GB, Hess AD, Gordon G et al. Thalidomide induction of bone marrow transplantation tolerance. Transplant Proc 1987; 19: 2658-2661.
308. Vogelsang GB, Hess AD, Santos GW. Thalidomide for treatment of graft-versus-host disease. Bone Marrow Transplant 1988; 3: 393-398.
309. Vogelsang GB, Hess AD,. Ling C et al. Thalidomide therapy of chronic graft-versus-host disease. Blood 1987; 70 (Suppl. 1): 315a.
310. Vogelsang GB, Santos GW, Colvin OM, Chen T. Thalidomide for graft-versus-host disease. Lancet 1988; 1: 827 (letter).
311. Vogelsang GB, Hess AD, Gordon G, Santos GW. Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model. Transplantation 1986; 41: 644-647.
312. Sampaio EP, Sarno EN, Galilly R et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991 173; 699-703.
313. Wood PM, Proctor SJ. The potential use of thalidomide in the therapy of graft-versus-host disease - a review of clinical and laboratory information. Leuk Res 1990; 14: 395-399.
314. Vogelsang GB, Wells MC, Santos GW et al. Combination low-dose thalidomide and cyclosporine prophylaxis for acute graft-versus-host disease in a rat mismatched model. Transplant Proc 1988; 20 (Suppl. 2): 226-228.
315. Vogelsang GB, Farmer ER, Hess AB et al. Thalidomide therapy of chronic graft-versus-host disease. New Engl J Med 1992; 26: 1055-1058.
316. Vogelsang GB. Thalidomide treatment for graft-versus-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds). Graft-versus-host disease: Immunology, Pathophysiology and Treatment. Marcel Dekker: New York, 1990, pp 293-300.
317. Heney D, Norfolk DR, Wheeldon J et al. Thalidomide treatment for chronic graft-versus-host disease. Br J Haematol 1991; 78: 23-27.
318. Lopez J, Ulibarrena C, Garcia-Larana J et al. Thalidomide as therapy for intestinal chronic GVHD. Bone Marrow Transplant 1993; 11. 251-252.
319. Smith SR, Terminelli C, Kenworthy-Bott L, Phillips DL. A study of cytokine production in acute graft-versus-host disease. Cell Immunol 1991; 134: 336-348.
320. Niederwieser D, Herold M, Woloszczuk W et al. Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation 1990; 50: 620-625.
321. Mowat A. Antibodies to IFN-Γ prevent immunological mediated intestinal damage to murine graft-versus-host reactions. Immunology 1989; 68: 18-24.
322. Nathan CF, Hibbs JB Jr. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opinion Immunol 1991; 3: 65-70.
323. Liew FY, Millott S, Parkinson C et al. Macrophage killing of Leischmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol 1990: 144: 4794-4797.
324. Garside P, Hutton AK, Severn A et al. Nitric oxide mediates intestinal pathology in graft-versus-host disease. Eur J Immunol 1992; 22: 2141-2145.
325. Drobyski WR, Keever CA, Hanson GA et al. Inhibition of nitric oxide production is associated with enhanced weight loss, decreased survival, and impaired alloengraftment in mice undergoing graft-versus-host disease after bone marrow transplantation. Blood 1994; 84: 2363-2373.
326. Harning R, Pelletier J, Lubbe K et al. Reduction in the severity of graft-versus-host disease and increased survival in allogeneic mice by treatment with monoclonal antibodies to cell adhesion antigens LFA-1α and MALA-2. Transplantation 1991; 52: 842-845.
327. LeDeist F, Blanche S, Keable S et al. Successful HLA nonidentical bone marrow transplantation in three patients with leukocyte adhesion deficiency. Blood 1989; 74: 512-516.
328. Van Dijken PJ, Ghayur T, Mauch P et al. Evidence that anti-LFA-1 in vivo improves engraftment and survival after allogeneic bone marrow transplantation. Transplantation 1990; 49: 882-886.
329. Atkinson K, Weller P, Ryman W, Biggs J. PUVA therapy for drug-resistant graft-versus-host disease. Bone Marrow Transplant 1986; 1: 227-236.
330. Bolwell B, Fishleder A, Lichtin A et al. Photopheresis in the treatment of chronic graft vs host disease (GVHD)(abstract). Blood 1990; 76 (Suppl. 1): 529a.
331. Hymes SR, Morison WL, Farmer ER et al. Methoxsalen and ultraviolet A radiation in the treatment of chronic cutaneous graft-versus-host reaction. J Am Acad Dermatol 1985; 12: 30-37.
332. Eppinger T, Ehninger G, Steinfert M et al. 8-methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Transplantation 1990; 50: 807-811.
333. Jampel RM, Farmer ER, Vogelsang GB et al. PUVA therapy for chronic cutaneous graft-vs-host disease. Arch Dermatol 1991; 127: 1673-1688.
334. Kapoor N, Pelligrini AE, Copelan EA et al. Psoralen plus ultraviolet A (PUVA) in the treatment of chronic graft versus host disease: preliminary experience in standard treatment resistant patients. Semin Hematol 1992; 29: 108-112.
335. Deeg HJ, Erickson K, Storb R, Sullivan KM. Photoinactivation of lymphohemopoietic cells: studies in transfusion medicine and bone marrow transplantation. Blood Cells 1992; 18: 151-162.
336. Satomi S, Sakurada M, Morimoto K et al. New method of immunosuppression by selective destruction of CTL by a photodynamic effect. Transplant Proc 1989; 21: 1134-1136.
337. Aubin F, Brion A, Deconinck E et al. Phototherapy in the treatment of cutaneous graft-versus-host disease. Our preliminary experience in resistant patients. Transplantation 1995; 59: 151-155.
338. Bierer BE, Mattila PS, Standaert RF et al. Two distinct signal transmission pathways in T lymphocytes are inhibited by alternative complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci USA 1990; 87: 9231-9235.
339. Dumont FJ, Melino MR, Staruch MJ et al. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol 1990; 144: 1418-1424.
340. Quesniaux VFJ, Wehrli S, Steiner C et al. The immunosuppressant rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo. Blood 1994; 84: 1543-1552.
341. Blazar BR, Taylor PA, Sehgal SN, Vallera DA. Rapamycin prolongs survival of murine recipients of fully allogeneic donor grafts when administered during the graft-versus-host disease process. Ann NY Acad Sci 1993; 685: 73-85.
342. Rothbard JB, Gefter ML. Interactions between immunogenic peptides and MHC proteins. Annu Rev Immunol 1991; 9: 527-565.
343. Schlegel PG, Aharoni R, Smilek DE et al. Prevention of graft-versus-host disease by peptides binding to class II major histocompatibility complex molecules. Blood 1994; 84: 2802-2810.
344. Wraith DC, Smilek DE, Mitchell DJ et al. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide mediated immunotherapy. Cell 1989; 59: 247-255.
345. Smilek DE, Lock CB, McDevitt HO. Antigen recognition and peptide-mediated immunotherapy in autoimmune disease. Immunol Rev 1990; 118: 37-71.
346. Hurtenbach U, Lier E, Adorni L, Nagy ZA. Prevention of autoimmune diabetes in non-obese diabetic mice by treatment with a class II major histocompatibility complex-blocking peptide. J Exp Med 1993; 177: 1499-1504.
347. Pless M, Gratwohl A, Tichelli A et al. 2-Chlorodeoxyadenosine as treatment of severe graft-versus-host disease. Blood 1994; 84: 987-989 (letter).
348. Michallet M, Corront B, Li V et al. Desferrioxamine and graft versus host disease (GVHD). Bone Marrow Transplant 1990; 5 (Suppl. 2): 117 (Abstr. 235).
349. Summerfield GP, Bellingham AJ, Bunch C, Woodrow JC. Successful treatment of chronic cutaneous graft-versus-host disease (GVHD) with penicillamine. Clin Lab Haematol 1983; 5: 313-318.
350. Kelley VE, Bacha P, Pankewycz O et al. Interleukin 2-diphtheria toxin fusion protein can abolish cell-mediated immunity in vivo. Proc Natl Acad Sci USA 1988; 85: 3980-3984.
351. 486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas. Leuk Lymphoma 1993; 11: 369-377.
352. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-1325.
353. Klintmalm GB, Ascher NL, Busuttil RW et al. RS-61443 for treatment-resistant human liver rejection. Transplant Proc 1993; 25: 697.
354. Sollinger HW, Deierhoi MH, Beizer FO et al. RS-61443 -a phase I clinical trial and pilot rescue study. Transplantation 1992; 53: 428-432.
355. Laskow DA, Deierhoi MH, Hudson SL et al. The incidence of subsequent acute rejection following the treatment of refractory renal allograft rejection with mycophenolate mofetil (RS61443). Transplantation 1994; 57: 640-643.
356. Howard M, O'Garra A. Biological properties of interleukin 10. Immunol Today 1992; 13: 198-200.
357. Spits H, de Waal Malefyt R. Functional characterization of human IL-10. Int Arch Allergy Immunol 1992; 99: 8-15.
358. 1 model of acute graft versus host disease. Transplantation 1995; 59: 890-896.
359. Takeuchi T, Iinuma H, Kunimoto S et al. A new antitumor antibiotic, spergualin: isolation and antitumor activity. J Antibiot (Tokyo) 1981; 34: 1619-1621.
360. Kasai M, Higa T, Naohara T et al. 15-Deoxyspergualin controls cyclosporin- and steroid-resistant intestinal acute graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14: 315-317.
361. Atkinson K, Matias C, Guiffre A et al In vivo administration of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF, interleukin-1 (IL-1), and IL-4, alone and in combination, after allogeneic murine hematopoietic stem cell transplantation. Blood 1991; 77: 1376-1382.
362. Allen RD, Staley TA, Sidman CL. Differential cytokine expression in acute
363. Symington FW, Symington BE, Liu PY et al. The relationship of serum IL-6 levels to acute graft-versus-host disease and hepatorenal disease after human bone marrow transplantation. Transplantation 1992; 54: 457-462.
364. Sykes M, Abraham VS, Harty MW, Pearson DA. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity. J Immunol 1993; 150: 197-205.
365. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor α during graft-versus-host disease. J Exp Med 1992; 175: 405-413.
366. Givon T, Revel M, Slavin S. Potential use of interleukin-6 in bone marrow transplantation: effects of recombinant human interleukin-6 after syngeneic and semiallogeneic bone marrow transplantation in mice. Blood 1994; 83: 1690-1697.
367. Umland SP, Razac S, Nahrebne DK, Seymour BW. Effects of in vivo administration of interferon (IFN)-gamma, anti-IFN-gamma, or anti-interleukin-4 monoclonal antibodies in chronic autoimmune graft-versus-host disease. Clin Immunol Immunopathol 1992; 63: 66-73.
368. Robinet E, Ibrahim A, Trunch A et al. Serum levels and receptor expression of tumor necrosis factor-alpha following human allogeneic and autologous bone marrow transplantation. Transplantation 1992; 53: 574-579.
369. Deeg HJ. Prophylaxis and treatment of acute graft-versus-host disease: current state, implications of new immunopharmacologic compounds and future strategies to prevent and treat acute GVHD in high-risk patients. Bone Marrow Transplant 1994; 14 (Suppl. 4): S56-S60.
370. Chang JY, Sehgal SN, Bansbach CC. FK506 and rapamycin: novel pharmacological probes of the immune response. Trends Pharmacol Sci 1991; 12: 218-223.
371. Dayton JS, Turka LA, Thompson CB, Mitchell BS. Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine and mycophenolic acid on T cell lymphocyte proliferation and purine ribonucleotide metabolism. Mol Pharmacol 1992; 41: 671-676.
372. Yuh DD, Morris RE. The immunopharmacology of immunosuppression by 15-deoxyspergualin. Transplantation 1993; 55: 578-591.
373. Jaffee BD, Jones EA, Zajac I et al. Effects of brequinar sodium on cynomolgus monkeys: immunosuppression and pharmacokinetics. Transplant Proc 1993; 25: 710-711.
374. Williams JW, Xiao F, Foster PF et al. Immunosuppressives effects of leflunomide in a cardiac allograft model. Transplant Proc 1993; 25: 745-746.